Blog

Yin Ling Woo: A big boost for the third pillar of cervical cancer elimination

Yin Ling Woo/LinkedIn

Nov 2, 2024, 21:19

Yin Ling Woo: A big boost for the third pillar of cervical cancer elimination

Yin Ling Woo, Professor of Obstetrics and Gynaecology at the University of Malaya, shared a post on LinkedIn by CRUK, adding:

“This is a big boost for the third pillar of cervical cancer elimination! Adding on a relatively simple chemotherapy regime (which is also helpful when radiotherapy services have a long waiting list) can improve survival rates and reduce recurrence.”

Quoting Cancer Research UK (CRUK)’s post:

“Researchers funded by Cancer Research UK have made the biggest improvement in cervical cancer treatment in more than 20 years by changing how we use existing drugs.

Results from the INTERLACE trial show that giving cervical cancer patients a short course of chemotherapy before starting the standard treatment cuts the risk of death 40%. The new approach also cuts the risk of cervical cancer returning or relapsing (growing again after responding to treatment) by 35%.

Around 3,300 women are diagnosed with cervical cancer each year in the UK (2017-2019). Sadly, there are around 860 yearly UK deaths from the disease (2018-2019, 2021).

Since 1999, doctors have treated it with a course of chemoradiation (CRT), a combination of chemotherapy and radiotherapy. The new study shows that six weeks of induction chemotherapy before CRT helps more people survive without their cancer returning.

After 5 years, 80% of trial participants who received induction chemotherapy followed by CRT were alive and 73% had not seen their cancer return or spread. By contrast, 72% of those who only received standard treatment were alive and 64% had not seen their cancer return or spread.

‘Timing is everything when you’re treating cancer,’ said Dr. Iain Foulkes, our executive director of research and innovation. ‘The simple act of adding induction chemotherapy to the start of chemoradiation treatment for cervical cancer has delivered remarkable results in this trial.’

And, because the two chemotherapy drugs used for the induction treatment are cheap, easily accessible and already approved for use, experts say they could become a new standard of care relatively quickly.

‘This is the biggest improvement in outcome in this disease in over 20 years,’ said Dr. Mary McCormack, the lead investigator of the trial from University College London’s Cancer Institute and University College London Hospital. ‘I’m incredibly proud of all the patients who participated in the trial; their contribution has allowed us to gather the evidence needed to improve treatment of cervical cancer patients everywhere.’

There’s hope the approach could also lead to similar breakthroughs for other cancers too.

‘A growing body of evidence is showing the value of additional rounds of chemotherapy before other treatments like surgery and radiotherapy in several other cancers,’ said Foulkes. ‘Not only can it reduce the chances of cancer coming back, it can be delivered quickly using drugs already available worldwide.’

This article was originally published when researchers presented preliminary results from the INTERLACE trial in October 2023. It has been updated to reflect the final results.”

Yin Ling Woo: A big boost for the third pillar of cervical cancer elimination